Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Buprenorphine
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Sublocade · DIN 02483084 · 100 mg/0.5 mL · injection solution- 0.5mL pre-filled syringe
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Free naloxone kits in Ontario: no prescription or health card needed; free kits at participating pharmacies and community sites
Free naloxone kits: eligibility and accessNo interchangeable product listed in the Ontario extract
Sublocade · DIN 02483084
Manufacturer: Indivior UK Limited; listing date 2020-04-30
Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 100 MG/0.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.
Ministry pays: $550.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02483084: Sublocade
Raw flags: sec3=Y
Item: 280812024; group id 414; item number 1019; lccId None; manufacturer id IND
Source form: Inj Sol- 0.5mL Pref Syr; strength: 100mg/0.5mL
Recorded listing: General benefit
Source prices (unrounded): $550.0000; ministry $550.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483084
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97348
Shortage status: resolved shortage (ended March 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483084
Shortage record checked October 6, 2026
Sublocade · DIN 02483092 · 300 mg/1.5 mL · injection solution- 1.5mL pre-filled syringe
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Sublocade · DIN 02483092
Manufacturer: Indivior UK Limited; listing date 2020-04-30
Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 300 MG/1.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.
Ministry pays: $550.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02483092: Sublocade
Raw flags: sec3=Y
Item: 280812025; group id 414; item number 1020; lccId None; manufacturer id IND
Source form: Inj Sol- 1.5mL Pref Syr; strength: 300mg/1.5mL
Recorded listing: General benefit
Source prices (unrounded): $550.0000; ministry $550.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483092
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97349
Shortage status: resolved shortage (ended March 2, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483092
Limited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.Discontinued June 30, 2023 · checked October 5, 2026
StatusLimited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 578 (criteria below); Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 578
Reason for Use code 578
For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria:
- The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant.
Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months.
The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy).
NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal.
Coverage limit:
LU Authorization Period: 2 years
No interchangeable product listed in the Ontario extract
Probuphine · DIN 02474921
Manufacturer: Knight Therapeutics Inc.; listing date 2020-04-30
Health Canada: Cancelled post market since 2023-06-30 · brand PROBUPHINE · ATC N07BC01 BUPRENORPHINE · form Implant · route Subcutaneous · ingredients BUPRENORPHINE HYDROCHLORIDE 80 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Probuphine: Formulary list price $1495.00 per unit (the source does not state the unit; exact figure $1495.0000). What the ministry pays, not the patient.
Ministry pays: $1495.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02474921: Probuphine
Raw flags: sec12=Y, sec3=Y
Item: 280812023; group id 416; item number 1027; lccId 00333; manufacturer id KNT
Source form: Subdermal Implant-Kit Pk; strength: 80mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1495.0000; ministry $1495.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474921
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515
Shortage status: discontinued (July 3, 2023, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474921
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 30, 2023 — choose a marketed DIN from the same-category list.
Buprenorphine & naloxone
Form:
10 of 10 products shown
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453908
Manufacturer: Actavis Pharma Company; listing date 2018-01-31
Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Act Buprenorphine/Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.
Ministry pays: $1.3350 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02453908: Act Buprenorphine/Naloxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id ACV
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3350; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453908
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94043Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350
Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453908
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424851
Manufacturer: Pharmascience Inc.; listing date 2015-02-26
Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Buprenorphine-Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.
Ministry pays: $1.3350 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02424851: PMS-Buprenorphine-Naloxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id PMS
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3350; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424851
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90952Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350
Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended October 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424851
DIN 02295695: Suboxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id IND
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $2.7261; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295695
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78104Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350
PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295695
Shortage record checked October 6, 2026
Suboxone · DIN 02502313 · 2 mg & 0.5 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502313
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 0.5 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502313: Suboxone
Raw flags: sec3=Y
Item: 280812032; group id 415; item number 1023; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $2.6700; ministry $2.6700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502313
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99189
Shortage status: resolved shortage (ended April 28, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502313
Shortage record checked October 6, 2026
Suboxone · DIN 02502321 · 4 mg & 1 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502321
Manufacturer: Indivior UK Limited; listing date 2026-02-27
Health Canada: Marketed since 2021-06-17 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 4 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 1 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502321: Suboxone
Raw flags: sec3=Y
Item: 280812033; group id 415; item number 1024; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 4mg & 1mg
Recorded listing: General benefit
Source prices (unrounded): $3.6889; ministry $3.6889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502321
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99190
Shortage status: resolved shortage (ended July 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502321
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453916
Manufacturer: Actavis Pharma Company; listing date 2018-01-31
Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Act Buprenorphine/Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.
Ministry pays: $2.3650 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02453916: Act Buprenorphine/Naloxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id ACV
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $2.3650; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453916
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94044Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650
Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453916
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424878
Manufacturer: Pharmascience Inc.; listing date 2015-02-26
Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Buprenorphine-Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.
Ministry pays: $2.3650 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02424878: PMS-Buprenorphine-Naloxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id PMS
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $2.3650; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424878
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90953Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650
Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended January 16, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424878
Shortage record checked October 6, 2026
Suboxone · DIN 02295709 · 8 mg & 2 mg · SL tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Suboxone · DIN 02295709
Manufacturer: Indivior UK Limited; listing date 2012-10-30
Health Canada: Marketed since 2016-04-01 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02295709: Suboxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id IND
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $4.8293; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295709
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78105Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650
PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295709
Shortage record checked October 6, 2026
Suboxone · DIN 02502348 · 8 mg & 2 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502348
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 2 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502348: Suboxone
Raw flags: sec3=Y
Item: 280812034; group id 415; item number 1025; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $4.7300; ministry $4.7300
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502348
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99191
Shortage status: resolved shortage (ended May 18, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502348
Shortage record checked October 6, 2026
Suboxone · DIN 02502356 · 12 mg & 3 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502356
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 12 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 3 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502356: Suboxone
Raw flags: sec3=Y
Item: 280812031; group id 415; item number 1026; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 12mg & 3mg
Recorded listing: General benefit
Source prices (unrounded): $7.0950; ministry $7.0950
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502356
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99192
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502356
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:08:12 Opiate Partial Agonists) and how they are covered
Matched class: 28:08:12 Opiate Partial Agonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
No displayed product is listed as a general benefit in this extract. Check its listing requirements below.
28:08:12 Opiate Partial Agonists
1 INDICATIONS
SUBLOCADE (buprenorphine solution (extended-release) for injection) is indicated for the
management of moderate to severe opioid use disorder in adult patients.
SUBLOCADE should be used as part of a complete treatment plan that includes counselling
and psychosocial support.
SUBLOCADE must only be administered subcutaneously by a healthcare professional (see 4
DOSAGE AND ADMINISTRATION).
1.1 Pediatrics
Pediatrics (˂18 years of age): No data are available in patients under 18 years of age.
SUBLOCADE is not indicated in pediatric patients.
1.2 Geriatrics
Geriatrics (≥ 65 years of age): There were no patients ≥ 65 years of age in the controlled
clinical trial of SUBLOCADE. In general, drug use for an elderly patient should be cautious,
reflecting the greater frequency of decreased hepatic, renal, respiratory and/or cardiac function,
concomitant disease or other drug therapies. If the decision is made to prescribe SUBLOCADE
to individuals 65 years of age or older, patients should be monitored for signs and symptoms of
toxicity or overdose.
https://pdf.hres.ca/dpd_pm/00082639.PDF
PM date: NOV 20, 2018
Source product: SUBLOCADE; DIN 02483084; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS
SUBOXONE® (buprenorphine and naloxone) is indicated for:
• substitution treatment in adults with problematic opioid drug dependence.
1.1 Pediatrics
Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the
safety and efficacy of SUBOXONE in pediatric patients has not been established; therefore,
Health Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (> 65 years of age): The safety and efficacy of SUBOXONE have not been established
in adults over 65 years of age.
In general, dose selection for an elderly patient should be cautious, usually starting at the low
end of the dosing range, reflecting the greater frequency of decreased hepatic, renal,
respiratory or cardiac function, concomitant disease or other drug therapy.
https://pdf.hres.ca/dpd_pm/00069997.PDF
PM date: MAY 17, 2007
Source product: SUBOXONE; DIN 02295695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Probuphine · DIN 02474921
Shortage status: discontinued (2023-07-03, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474921
Suboxone · DIN 02295695
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295695
Suboxone · DIN 02295709
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295709